The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Bayer; BMS Brazil
Research Funding - MaxiVax (Inst)
Travel, Accommodations, Expenses - Bayer; BMS Brazil
Investigation of metformin (MET) in patients with castration resistant prostate cancer (CRPC) in combination with enzalutamide (ENZ) vs. ENZ alone: A randomized, open label, phase 2 trial. SAKK 08/14—IMPROVE.
 
Christian Alexander Rothermundt
Consulting or Advisory Role - Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst)
Research Funding - Astellas Pharma (Inst)
 
Richard Cathomas
Consulting or Advisory Role - Amgen (Inst); Astellas Oncology (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Research Funding - Janssen (Inst)
 
Alexandros Xyrafas
No Relationships to Disclose
 
Martina Schneider
No Relationships to Disclose
 
Christine Biaggi Rudolf
No Relationships to Disclose
 
Enrico Roggero
Consulting or Advisory Role - Astellas Oncology; Bayer; Sanofi/Aventis
 
Natalie Fischer
Travel, Accommodations, Expenses - Abbvie; Celgene; SERVIER
 
Sacha Rothschild
Consulting or Advisory Role - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Lilly (Inst); Merck Serono (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Lilly; Merck Sharp & Dohme; Roche Pharma AG
 
Anna Patrikidou
No Relationships to Disclose
 
Walter B. Mingrone
Stock and Other Ownership Interests - Amgen; Karyopharm Therapeutics; Teva
Travel, Accommodations, Expenses - Amgen
 
Thomas Hermanns
No Relationships to Disclose
 
Tobias Wehrhahn
Consulting or Advisory Role - Astellas Oncology; BMS Brazil; Eisai; Genzyme; Novartis; Roche; Sanofi
Travel, Accommodations, Expenses - Astellas Oncology; BMS Brazil; Eisai; Genzyme; Novartis; Roche; Sanofi
 
Andreas Erdmann
No Relationships to Disclose
 
Beat Mueller
No Relationships to Disclose
 
Pierre Oliver Bohanes
Honoraria - Abbvie; Celgene; Lilly; Merck; Sanofi
Travel, Accommodations, Expenses - Amgen; Bayer; BMS Brazil; Boehringer Ingelheim; Lilly
 
Karin Ribi
No Relationships to Disclose
 
Silke Gillessen
Consulting or Advisory Role - Active Biotech (Inst); Active Biotech (Inst); Advanced Accelerator Applications (Inst); Advanced Accelerator Applications (Inst); Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); CureVac (Inst); Curevac (Inst); Ferring (Inst); Ferring (Inst); Innocrin Pharma (Inst); Janssen (Inst); MaxiVax ; Novartis (Inst); Orion (Inst); Roche (Inst); Sanofi; Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Method for biomarker (WO 3752009138392 A1)
Travel, Accommodations, Expenses - Diverse Companies
Other Relationship - Astellas Medivation; ESSA; Nektar; ProteoMediX